Title (en)

TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES

Title (de)

BEHANDLUNG VON HERZ-KREISLAUF-KRANKHEITEN UND DYSLIPIDÄMIE MIT HEMMERN DER SEKRETORISCHEN PHOSPHOLIPASE A2 (SPLA2) UND SPLA2-HEMMER-KOMBINATIONSTHERAPIEN

Title (fr)

TRAITEMENT DES MALADIES CARDIOVASCULAIRES ET DE LA DYSLIPIDÉMIE AU MOYEN D'INHIBITEURS DE LA PHOSPHOLIPASE A<SB>2</SB>SÉCRÉTOIRE (SPLA<SB>2</SB>) ET THÉRAPIES COMBINÉES IMPLIQUANT DES INHIBITEURS DE LA SPLA<SB>2</SB>

Publication

EP 2154958 A1 20100224 (EN)

Application

EP 08747605 A 20080502

Priority

- US 2008062577 W 20080502
- US 91591007 P 20070503
- US 96959107 P 20070831
- US 87486907 A 20071018

Abstract (en)

[origin: WO2008137803A1] Administration of SPLA₂ inhibitors has been found to decrease cholesterol levels, atherosclerotic plaque formation and aortic aneurysm in mice, and to decrease cholesterol and triglyceride levels in humans. Interestingly, administration of SPLA₂ inhibitors was found to decrease cholesterol levels even when the inhibitors were administered only once per day. Therefore, provided herein are methods of treating dyslipidemia, CVD, and conditions associated with CVD such as atherosclerosis and metabolic syndrome, by administering one or more sPLA₂ inhibitors. Significantly, administration of SPLA₂ inhibitors and various compounds used in the treatment of CVD, such as for example statins, resulted in greater decreases in LDL and LDL particle levels in a synergistic manner. In addition, administration of sPLA₂ inhibitors and statins resulted in a synergistic decrease in plaque content. Therefore, also provided herein are compositions comprising one or more SPLA₂ inhibitors and one or more compounds used in the treatment of CVD, such as for example statins, and methods of using these compositions to treat dyslipidemia, CVD, and conditions associated with CVD such as atherosclerosis and metabolic syndrome.

IPC 8 full level

A01N 37/10 (2006.01); **A61K 31/19** (2006.01); **A61K 31/404** (2006.01); **A61K 45/06** (2006.01); **A61P 9/10** (2006.01)

CPC (source: EP)

A61K 31/19 (2013.01); **A61K 31/404** (2013.01); **A61K 45/06** (2013.01); **A61P 3/06** (2017.12); **A61P 3/10** (2017.12); **A61P 9/00** (2017.12); **A61P 9/10** (2017.12); **A61P 29/00** (2017.12)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA MK RS

DOCDB simple family (publication)

WO 2008137803 A1 20081113; AU 2008247451 A1 20081113; BR PI0811486 A2 20140930; CA 2686157 A1 20081113; CN 101742907 A 20100616; EA 200971020 A1 20101029; EP 2154958 A1 20100224; EP 2154958 A4 20110504; JP 2010526152 A 20100729

DOCDB simple family (application)

US 2008062577 W 20080502; AU 2008247451 A 20080502; BR PI0811486 A 20080502; CA 2686157 A 20080502; CN 200880023061 A 20080502; EA 200971020 A 20080502; EP 08747605 A 20080502; JP 2010507578 A 20080502